… Here we evaluated antibodies forming the basis of five mAb therapies in clinical … vivo efficacy
against infection by SARS-CoV-2 variants. Monotherapy with LY-CoV555, an antibody that …

… theoretical maximum monoclonal antibody efficacy, which assumes that endogenous
neutralising antibody responses provide the same protection as monoclonal antibody treatment. If …

… IgA ASC (antibody secreting cells) were the most important immune parameter to predict
protection from the oral immunization. VXA-CoV2-1 could have a broader activity against …

… of anti-SARS-CoV-2 monoclonal antibodies with optimized … Fcγ receptors results in improved
efficacy in both preventing and … to confer full protection against SARS-CoV-2 challenge and …

… SARS-CoV-2 antibody products were defined as treatments involving exogenous antibodies
that act upon epitopes on SARS-CoV… to anti-SARS-CoV-2 antibody products were based …

… antibodies for SARS-CoV-2 infection, even in some with high antibody titers. However,
the occurrence of reinfection is rare for over 7 months of follow-up after the first antibody-positive …

… antibody concentrations can predict the efficacy is also uncertain. We aimed to assess the
efficacy of these vaccines in preventing SARS-CoV-… the antibody concentrations and efficacy. …

… The primary efficacy outcome was hospitalization (… antibody that neutralizes all sarbecoviruses
would target a highly conserved epitope that would be functionally retained as SARS-CoV…

… To evaluate the efficacy of IgG1 ab1 in vivo we used two mouse models of SARS-CoV-2 …
The first one is based on the recently developed mouse ACE2-adapted SARS-CoV-2 which has …

… predictive of the efficacy of both monoclonal antibodies (p<0·… the dose administered and
efficacy in preventing hospitalisation (… antibody was expected to provide more than 30% efficacy …